Registry for diagnosing and managing AL amyloidosis in Europe

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This initiative aims to create a comprehensive registry of new cases of AL amyloidosis across Europe, focusing on patients evaluated at referral centers. It will establish a biorepository and sample sharing network to investigate the disease mechanisms using advanced molecular technologies and big data analysis. The project seeks to enhance early diagnosis, understand the disease's natural history, and refine techniques for detecting minimal residual disease in patients who have responded to therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* diagnosis of systemic AL amyloidosis;
* treatment-naïve;
* age ≥18 years;
* ability to understand and willingness to sign an informed consent;
* planned follow-up at participating center.

Exclusion Criteria:

* non-AL amyloidosis;
* previous treatment for AL amyloidosis.

Where it's running

• Medical Department, Amyloidosis Center, University Hospital, Im Neuenheimer Feld 672
  Heidelberg, Germany Recruiting
• Fondazione IRCCS Policlinico San Matteo, Pavia, Viale Golgi 19, 27100
  Pavia, Italy Recruiting
• UMC Utrecht, dept Hematology, Amyloid Expertise Center, Utrecht, Heidelberglaan
  Utrecht, Netherlands Recruiting
• Instituto de Investigación Sanitaria de Navarra (IdiSNA) C. de Irunlarrea, 3, 31008 Pamplona, Navarra
  Pamplona, Spain Recruiting
• Universidad de la Republica Hospital de Clinicas "Dr Manuel Quintela"
  Montevideo, Uruguay Recruiting
• University of Applied Sciences and Arts Northwestern Switzerland, Institute of Medical Engineering and Medical Informatics
  Muttenz, Switzerland Active not recruiting

Study contacts

• Study coordinator: Giovanni Palladini
• Email: segreteria.amiloidosi@smatteo.pv.it
• Phone: +390382502994

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Hungarian National Systemic Amyloidosis Registry

  This registry collects medical data from adults with systemic amyloidosis across Hungary to help understand how the disease is diagnosed and treated in real-world practice.

  Recruiting at 12 sites Semmelweis University · Balatonfüred and 11 other locations · NCT07689331

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• How the IGLV1-44 light chain causes AL amyloidosis and POEMS

  This project tests whether specific IGLV1-44 light‑chain sequences drive AL amyloidosis and POEMS and whether nanobodies can recognize and stabilize those light chains in adults with AL amyloidosis, POEMS, or multiple myeloma.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07448935

• How N-glycosylation of light chains affects AL amyloidosis diagnosis and treatment

  This project will test whether a sugar modification called N-glycosylation on immunoglobulin light chains helps cause disease or changes how AL amyloidosis and related monoclonal gammopathies behave in adults.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, PV · NCT07448779

• Belgian Amyloidosis Biobank and Patient Registry at UZ Leuven

  This project collects and stores blood, tissue samples, and medical data from adults with suspected or confirmed amyloidosis to create a biobank and registry for future research.

  Recruiting at 2 sites Universitaire Ziekenhuizen KU Leuven · Leuven and 1 other locations · NCT07172243

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.